Register

Downloads / CME Credit

Chair & Presenters

Angela Schulz MD, PhD
Chair & Presenter
Angela Schulz, MD, PhD
University Medical Center Hamburg
Hamburg, Germany
Emily de los Reyes, MD
Co-Presenter
Emily de los Reyes, MD
The Ohio State University
Nationwide Children’s Hospital
Columbus, Ohio
Elaine Wirrell, MD
Co-Presenter
Elaine Wirrell, MD
Mayo Clinic
Rochester, Minnesota

Location

Walter E. Washington Convention Center
801 Mt Vernon Pl NW
Washington, DC 20001
Room 147 (Street Level)

Agenda

6:00 PM  Registration and Dinner

6:30 PM  Welcome, Introduction, and Polling

6:45 PM  Perspectives on Pathogenesis, Symptomatology, and Diagnosis of Neuronal Ceroid LipofuscinosesElaine Wirrell, MD
Science Behind the Story
PeerView Talks: Story Behind the Science

7:05 PM  Contemporary Monitoring and Management Strategies for CLN2 Disease: Current Strengths and PitfallsEmily de los Reyes, MD
Science Behind the Story
PeerView Talks: Story Behind the Science

7:25 PM  Taking Stock of Breakthroughs in the Treatment of Late Infantile CLN2 Disease: How Might Novel Therapy Change the Standard of Care?Angela Schulz, MD, PhD
Science Behind the Story
PeerView Talks: Story Behind the Science

7:45 PM  Q&A and Concluding Remarks

CME Information

Activity Description & Educational Objectives

A pediatric-onset, autosomal recessive, neurodegenerative lysosomal storage disorder that typically manifests between between the ages of 2 and 4 years, late infantile neuronal ceroid lipofuscinosis (CLN2) is caused by a deficiency in activity tripeptidyl peptidase 1 and characterized clinically by seizures, language delays, ataxia, movement disorders, motor deterioration, dementia, blindness, and early death. In this PeerView Live satellite symposium, a panel of experts will highlight the importance of early diagnosis, discuss monitoring and management strategies, and assess the impact of the latest breakthroughs on the treatment of CLN2 disease. In addition to the data, each panelist will share their “Story Behind the Science”—personal stories about the patients and families who are most impacted by this disease.

Upon completion of this activity, participants should be better able to:

Target Audience

This activity has been designed to meet the educational needs of neurologists, pediatric neurologists, pediatric neurophysiologists, geneticists, genetic counselors, and other clinicians involved in the management of CLN2 disease.

Requirements for Successful Completion

In order to receive credit, participants must attend the live activity and complete the request for credit. There are no prerequisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon completion of the request for credit at the end of the post-test.

Media: Symposium
Release and Expiration Date: December 1, 2017
Time to Complete: 90 minutes

Faculty & Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity during the past 12 months.

Chair & Presenter

Angela Schulz, MD, PhD
Department of Paediatrics
University Medical Center Hamburg
Hamburg, Germany

Co-Presenters

Emily de los Reyes, MD
Clinical Professor of Pediatrics and Neurology
The Ohio State University
Dept of Pediatric Neurology
Nationwide Children’s Hospital
Director: Batten’s disease Center of Excellence
Columbus, Ohio

Elaine Wirrell, MD
Director of Pediatric Epilepsy
Professor of Neurology
Mayo Clinic
Rochester, Minnesota

Medical Director

Kirk A. Tacka, PhD
PVI, PeerView Institute for Medical Education

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit & Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership

This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by an educational grant from BioMarin Pharmaceuticals Inc.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.